Cytophage Technologies Ltd.
CYTO.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.23% | -15.89% | |||
| Depreciation & Amortization | -26.65% | 39.32% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.75% | -5.80% | |||
| Operating Income | -0.75% | 5.80% | |||
| Income Before Tax | -1.00% | 8.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.00% | 8.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.00% | 8.92% | |||
| EBIT | -0.75% | 5.80% | |||
| EBITDA | -8.23% | 13.07% | |||
| EPS Basic | 2.00% | 9.09% | |||
| Normalized Basic EPS | 2.13% | 3.09% | |||
| EPS Diluted | 2.00% | 9.09% | |||
| Normalized Diluted EPS | 2.13% | 3.09% | |||
| Average Basic Shares Outstanding | 3.19% | -0.02% | |||
| Average Diluted Shares Outstanding | 3.19% | -0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||